Millennium Management LLC Purchases 1,008,760 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX)

Millennium Management LLC increased its position in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) by 369.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,281,629 shares of the company’s stock after purchasing an additional 1,008,760 shares during the period. Millennium Management LLC owned about 1.81% of Ventyx Biosciences worth $2,807,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of the company. American Century Companies Inc. increased its position in shares of Ventyx Biosciences by 12.4% during the fourth quarter. American Century Companies Inc. now owns 67,329 shares of the company’s stock valued at $147,000 after purchasing an additional 7,414 shares during the period. Wells Fargo & Company MN increased its position in shares of Ventyx Biosciences by 23.3% during the fourth quarter. Wells Fargo & Company MN now owns 41,170 shares of the company’s stock valued at $90,000 after purchasing an additional 7,768 shares during the period. Barclays PLC increased its position in shares of Ventyx Biosciences by 14.2% during the fourth quarter. Barclays PLC now owns 91,669 shares of the company’s stock valued at $200,000 after purchasing an additional 11,374 shares during the period. Catalina Capital Group LLC bought a new stake in shares of Ventyx Biosciences during the fourth quarter valued at approximately $25,000. Finally, MetLife Investment Management LLC increased its position in shares of Ventyx Biosciences by 76.0% during the fourth quarter. MetLife Investment Management LLC now owns 26,731 shares of the company’s stock valued at $59,000 after purchasing an additional 11,543 shares during the period. 97.88% of the stock is currently owned by institutional investors.

Ventyx Biosciences Price Performance

Shares of NASDAQ:VTYX opened at $1.68 on Friday. The business’s fifty day moving average price is $1.25 and its two-hundred day moving average price is $1.72. Ventyx Biosciences, Inc. has a fifty-two week low of $0.78 and a fifty-two week high of $5.66. The stock has a market capitalization of $119.19 million, a price-to-earnings ratio of -0.71 and a beta of 0.73.

Ventyx Biosciences (NASDAQ:VTYX) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.39) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.09. Research analysts expect that Ventyx Biosciences, Inc. will post -2.09 EPS for the current fiscal year.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.